Partnership insights
Collaborating, innovating, and finding new ways together to improve outcomes
Much more can be achieved when all players in the life sciences and pharmaceutical industries work together, in a truly collaborative way. At ICON, this means working in a way that goes beyond a traditional CRO. It means being a trusted partner.
Exploring partnership culture and its impact on outsourcing and operational strategy
Partnership culture within the clinical research industry has often been overlooked as a component of a successful outsourcing strategy. However, culture can support, inform, and maintain strategies and operational decision-making.
Webinar: Exploring partnership culture and its impact on outsourcing and operational strategy
In this webinar, Sanofi and ICON discuss how they created a shared partnership/alliance culture, which has evolved both the outsourcing strategy and operating model. Attendees will learn about the specific tools and methods used to develop and support the Sanofi / ICON partnership, including:
- Adaptation of the 9 Box Grid to assess cultural alignment and outsourcing and operational strategy, identifying areas of strength and opportunities for development
- An “ABCs of Culture” framework, designed to build cross-organisational cultural alignment.
The evolving relationship between sponsors and CROs
In this Q&A and accompanying podcast, Jeff James provides his perspectives on how CROs have matured to become true partners that offer expansive clinical trial and drug development services, and he spotlights ICON’s approach towards collaboration.
Sponsor and CRO pharmacovigilance and safety alliances
This whitepaper outlines the best practices and model options for ensuring success when outsourcing pharmacovigilance and patient safety services.
Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
Engaging physicians to support and increase clinical research activity
More and more healthcare institutions are looking to increase their research portfolio however engagement of busy physicians is always a challenge.
-
Blog: How joint venture models can boost Japan’s pharmaceutical industry
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
-
Media article: How this top CEO helped Pfizer turbocharge the covid-19 vaccine
Steve Cutler discusses ICON's covid-19 efforts, the importance of building a good team, and more in this interview with Investor's Business Daily.
-
Media article: Will big tech dominate healthcare in the years ahead?
Louisa Roberts, VP of Corporate Development and Partnerships, considers the benefits of partnerships with tech companies.
-
Media article: How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
-
Media article: The importance of partnering for bioanalytical studies
BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
-
Blog: The Importance of partnering for bioanalytical studies
Bioanalytical studies are an important aspect of biologic drug development that may necessitate partnering with bioanalysis experts.
-
Blog: Exploring the benefits of biotech partnerships
From patient-centricity to venture capital networks.
-
Blog: Global Outsourcing Strategies
As the market for outsourcing continues to grow, so too have the types of outsourcing models available to sponsors.
